HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating for Prelude Therapeutics (NASDAQ:PRLD) and maintained a price target of $5.
October 28, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Prelude Therapeutics, maintaining a $5 price target, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst suggests positive sentiment and potential upside for Prelude Therapeutics. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100